Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    1,2 Diaminocyclohexane Platinum Oxalate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 34,039Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MediciNova Completes MN-166 Enrollment in CIPN Prevention Trial
    MediciNova Completes MN-166 Enrollment in CIPN Prevention Trial

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207535/7767/en/MediciNova-Announces-Completion-of-Patient-Enrollment-Evaluating-MN-166-ibudilast-in-the-Prevention-of-Chemotherapy-induced-Peripheral-Neuropathy.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Az's Imfinzi Bags Perioperative Nod In Early-Stage Stomach Cancer
    Az's Imfinzi Bags Perioperative Nod In Early-Stage Stomach Cancer

    25 Nov 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/azs-imfinzi-expands-its-perioperative-prowess-early-stage-stomach-cancer-fda-nod

    FIERCE PHARMA
    25 Nov 2025
    Share Share
    Stomach Cancer Awareness Month
    Stomach Cancer Awareness Month

    01 Nov 2025

    // PRESS RELEASE

    https://www.nanoalvand.com/index.php/en/blog-en/9-news/215-stomach-cancer-awareness-month

    PRESS RELEASE
    01 Nov 2025
    Share Share
    Cadonilimab Shows OS Gain In 1st-Line Advanced Gastric Cancer
    Cadonilimab Shows OS Gain In 1st-Line Advanced Gastric Cancer

    19 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/significant-os-benefit-with-cadonilimab-in-first-line-advanced-gastric-cancer-final-analysis-of-compassion-15-presented-at-esmo-2025-302588409.html

    PR NEWSWIRE
    19 Oct 2025
    Share Share
    Imfinzi Cuts Death Risk 22% in Early Gastric Cancer Ph3
    Imfinzi Cuts Death Risk 22% in Early Gastric Cancer Ph3

    17 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251017239598/en/IMFINZI-durvalumab-based-regimen-reduced-the-risk-of-death-by-22-in-early-gastric-cancer-vs.-chemotherapy-alone-in-MATTERHORN-Phase-III-trial

    BUSINESSWIRE
    17 Oct 2025
    Share Share
    Korea University Study: Age 70 Cutoff for Colorectal Cancer
    Korea University Study: Age 70 Cutoff for Colorectal Cancer

    18 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/korea-university-study-identifies-age-70-as-cutoff-for-chemotherapy-benefit-in-colorectal-cancer-302560004.html

    PR NEWSWIRE
    18 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.